[
  {
    "ts": "2026-01-16T11:00:20+00:00",
    "headline": "AbbVie Inc.'s (NYSE:ABBV) institutional investors lost 3.3% last week but have benefitted from longer-term gains",
    "summary": "Key Insights Institutions' substantial holdings in AbbVie implies that they have significant influence over the...",
    "url": "https://finance.yahoo.com/news/abbvie-inc-nyse-abbv-institutional-110020101.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "8b953de0-c7f9-3bff-bd40-34c14d1227a1",
      "content": {
        "id": "8b953de0-c7f9-3bff-bd40-34c14d1227a1",
        "contentType": "STORY",
        "title": "AbbVie Inc.'s (NYSE:ABBV) institutional investors lost 3.3% last week but have benefitted from longer-term gains",
        "description": "",
        "summary": "Key Insights Institutions' substantial holdings in AbbVie implies that they have significant influence over the...",
        "pubDate": "2026-01-16T11:00:20Z",
        "displayTime": "2026-01-16T11:00:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-inc-nyse-abbv-institutional-110020101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-inc-nyse-abbv-institutional-110020101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T13:53:40+00:00",
    "headline": "JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency",
    "summary": "AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology pipeline.",
    "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-abbvie-highlights-growth-drivers-as-it-moves-away-from-humira-dependency/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "3944fd08-dcb3-3f2e-84a8-e3170360eb16",
      "content": {
        "id": "3944fd08-dcb3-3f2e-84a8-e3170360eb16",
        "contentType": "STORY",
        "title": "JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency",
        "description": "",
        "summary": "AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology pipeline.",
        "pubDate": "2026-01-16T13:53:40Z",
        "displayTime": "2026-01-16T13:53:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/5a73e3acae5c5128be094278c3d67770",
          "originalWidth": 1440,
          "originalHeight": 959,
          "caption": "AbbVie secures revenues after patent expiration for Humira through growth of immunology and neurology franchises. Credit: ChrisStock82/Shutterstock.com",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xs97V5QyVK0wFkMMqAgQJg--~B/aD05NTk7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/5a73e3acae5c5128be094278c3d67770.cf.webp",
              "width": 1440,
              "height": 959,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YKkV6z3nYS0Tsm.W6NZsiw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/5a73e3acae5c5128be094278c3d67770.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-abbvie-highlights-growth-drivers-as-it-moves-away-from-humira-dependency/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-abbvie-highlights-growth-drivers-135340880.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "TEVA"
            },
            {
              "symbol": "OGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T18:43:00+00:00",
    "headline": "AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
    "summary": "AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])*. Improvements were observed in complete response rates (CRR), durat",
    "url": "https://finance.yahoo.com/news/abbvie-announces-topline-results-epcoritamab-184300468.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "e849664a-f3f4-3f56-b85f-4359e8fdd688",
      "content": {
        "id": "e849664a-f3f4-3f56-b85f-4359e8fdd688",
        "contentType": "STORY",
        "title": "AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
        "description": "",
        "summary": "AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])*. Improvements were observed in complete response rates (CRR), durat",
        "pubDate": "2026-01-16T18:43:00Z",
        "displayTime": "2026-01-16T18:43:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/c92c93d59542d5bc54ffec83cbbf937e",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LSfJD6BPA9r1kuSHZDkruw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/c92c93d59542d5bc54ffec83cbbf937e.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XbFhL64_f.W21CTXng252w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c92c93d59542d5bc54ffec83cbbf937e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-announces-topline-results-epcoritamab-184300468.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-announces-topline-results-epcoritamab-184300468.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "GMAB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]